S/N 05/520,130

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

ARATHOON ET AL.

Examiner:

A. HOLLERAN

Serial No.:

09/520,130

Group Art Unit:

1642

Filed:

MARCH 7, 2000

Docket No.:

11669.132USC1

Confirmation No.:

1353

Customer No.:

23552

Title:

A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES

HAVING HETEROMULTIMERIC AND COMMON COMPONENTS

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408488506 US

Date of Deposit: July 26, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

07/28/2004 EABUBAK1 00000119 09520130

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C. P.O. Box 2903 Minneapolis, Minnesota 55402-0903 (612) 332-5300

Date: July Le

Katherine M. Kowalchyk

Reg. No. 36,848

KMK:sab

22552

PATENT TRADEMARK OFFICE

Date Mailed: July 26, 2004 Sheet 1 of 1

FORMIED	NFORMATION DISCLOSURE STATEMENT	Docket Number: Application Number: 11669.132USC1 09/520,130				
JUL 2 6 2004 &	in an application	Applicant: ARATHOON ET A	Applicant: ARATHOON ET AL.			
	(Use several sheets if necessary)	Filing Date: MARCH 7, 2000	Group Art Unit: 1642			

TRA:								
			U	.s. patent document	rs			
EXAMINER INITIAL	DOCUM	ENT NO.	DATE	NAME	CLASS	SUBCLASS		G DATE OPRIATE
				_				
							i i	_
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NO.		NO. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
								
•	•	OTHER	DOCUMENTS	S (Including Author, Title, D	Date, Pertinent F	Pages, Etc.)		
	Luo, D. et al., "V1-Linker-Vh Orientation-Dependent Expression of Single Chain Fv Containing an Engineered Disulfide-Stabilized Bond in the Framework Regions", J. Biochem., 118:825-831 (1995)							
		Nieba, L. et al., "Disrupting the hydrophobic patches at the antibody variable/constant domain interace: improved in vivo folding and physical characterization of an engineered scFv fragment", Protein Engineering, 10(4):435-444 (1997)						
		Reiter, Y. et al., "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv", Protein Engineering, 7(5):697-704 (1994)						
				· · · · ·				

23552
PATENT TRADEMARK OFFICE

EXAMINER DA	ATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.